Patents for Humira (adalimumab) don’t have a single expiration date. There are many patent families (composition of matter, formulations, dosing methods, manufacturing processes, use claims, etc.) and expiry dates vary by country and by patent.
A rough picture:
- United States: The core adalimumab composition-of-matter patents have expired or are expiring, but there are additional patents and regulatory data/exclusivity that have in some cases extended protection into the mid-2020s. This is one reason biosimilars began to enter consideration and certain markets around 2023–2024, with timing affected by settlements and payer deals.
- European Union: Patents and regulatory exclusivities generally allowed biosimilar competition to begin earlier (roughly 2018–2019 in many parts of Europe), though individual patent terms still vary by claim and country.
- Other jurisdictions: Expiry dates vary similarly, depending on local patent law, extensions, and exclusivity rules.
Because the status depends on jurisdiction and which patent family you care about, if you want a precise answer, tell me:
- the country or region you’re interested in (US, EU, UK, etc.),
- whether you want the expiry of the core composition patent or other patents (formulations, uses, manufacturing),
- and whether you want the current status as of today.
I can then pull the specific expiry dates from patent databases and regulatory resources (USPTO, EPO, FDA/Purple Book, etc.).